Mometasone Furoate; Olopatadine Hydrochloride Patent Expiration

Mometasone Furoate; Olopatadine Hydrochloride is used for treating seasonal allergic rhinitis through nasal administration of a combination of olopatadine hydrochloride and mometasone furoate. It was first introduced by Glenmark Specialty Sa in its drug Ryaltris on Jan 13, 2022.


Mometasone Furoate; Olopatadine Hydrochloride Patents

Given below is the list of patents protecting Mometasone Furoate; Olopatadine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ryaltris US10016443 Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10376526 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10517880 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10548907 Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10561672 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10646500 Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10758550 Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US10765686 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US11400101 Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US11679210 Dispensing device and pharmaceutical composition for the treatment of rhinitis Sep 03, 2038 Glenmark Speclt
Ryaltris US9078923 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US9370483 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US9750754 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt
Ryaltris US9937189 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep 04, 2034 Glenmark Speclt


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mometasone Furoate; Olopatadine Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Mometasone Furoate; Olopatadine Hydrochloride.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 21 Feb, 2024 US10765686
Payment of Maintenance Fee, 4th Year, Large Entity 14 Feb, 2024 US10758550
Payment of Maintenance Fee, 8th Year, Large Entity 06 Dec, 2023 US9370483
Payment of Maintenance Fee, 4th Year, Large Entity 25 Oct, 2023 US10646500
Payment of Maintenance Fee, 4th Year, Large Entity 02 Aug, 2023 US10561672
Post Issue Communication - Certificate of Correction 31 Jul, 2023 US10016443
Payment of Maintenance Fee, 4th Year, Large Entity 19 Jul, 2023 US10548907
Electronic Review 29 Jun, 2023 US10016443
Email Notification 29 Jun, 2023 US10016443
Mail Pet Dec Routed to Certificate of Corrections Branch 28 Jun, 2023 US10016443



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳